Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 | Q13639 | 11/20 | 0.47 |
| ▸ | HTR2A | P28223 | 9/20 | 0.47 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | GSK3B | P49841 | 3/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | HRH1 | P35367 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3604667 | 0.91 | HTR2A (0.46) | HTR4HTR2AGSK3BKCNH2DRD2 | |
| SCHEMBL3594416 | 0.88 | GSK3B (0.48) | HTR4HTR2AKMT2AGSK3BKCNH2 | |
| SCHEMBL3598634 | 0.87 | NPC1 (0.49) | HTR2ACACNA1GKCNH2DRD2 | |
| SCHEMBL3589692 | 0.86 | HTR4 (0.62) | HTR4HTR2AGSK3BKCNH2 | |
| Hydrochloric Acid SCHEMBL3591507 | 0.86 | HTR4 (0.54) | HTR4HTR2AGSK3BKCNH2 | |
| Hydrochloric Acid SCHEMBL3595045 | 0.85 | HTR4 (0.61) | HTR4HTR2AGSK3BKCNH2 | |
| SCHEMBL3594752 | 0.83 | KCNH2 (0.54) | HTR4HTR2AGSK3BKCNH2 | |
| Hydrochloric Acid SCHEMBL3584914 | 0.83 | GSK3B (0.58) | HTR4HTR2AGSK3BKCNH2 | |
| Hydrochloric Acid SCHEMBL3589590 | 0.82 | HTR4 (0.63) | HTR4HTR2AGSK3BKCNH2 | |
| Hydrochloric Acid SCHEMBL3587419 | 0.76 | PTGER4 (0.52) | HTR4HTR2AGSK3BKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8507528-B2 | 2-alkyl-indazole compounds for the treatment of certain cns-related disorders | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2013-08-13 | — | — | US | disclosed |
| EP-2099780-B1 | 2 -ALKYL- INDAZOLE COMPOUNDS FOR THE TREATMENT OF CERTAIN CNS-RELATED DISORDERS | ACRAF (IT) | 2013-01-09 | — | — | EP | disclosed |
| US-20100056573-A1 | 2-ALKYL-INDAZOLE COMPOUNDS FOR THE TREATMENT OF CERTAIN CNS-RELATED DISORDERS | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2010-03-04 | — | — | US | disclosed |
| EP-2099780-A1 | 2 -ALKYL- INDAZOLE COMPOUNDS FOR THE TREATMENT OF CERTAIN CNS-RELATED DISORDERS | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A. (IT) | 2009-09-16 | — | — | EP | disclosed |
| WO-2008061688-A1 | 2 -ALKYL- INDAZOLE COMPOUNDS FOR THE TREATMENT OF CERTAIN CNS-RELATED DISORDERS | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056573-A1 | 2-ALKYL-INDAZOLE COMPOUNDS FOR THE TREATMENT OF CERTAIN CNS-RELATED DISORDERS | CYP11B2, CYP1A2, INA | HTR4 564/4885HTR2A 263/4885CACNA1G 757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.